Last updated: February 21, 2026
What is the Focus of Patent AU2016354007?
Patent AU2016354007 covers a novel pharmaceutical composition associated with specific therapeutic applications. The patent's primary claims protect a composition comprising certain active ingredients, their methods of preparation, and use in treating particular conditions. The invention relates mainly to advanced drug formulations or therapeutic methods, with implications for pharmaceutical innovation in Australia.
Patent Claims Overview
Key Claims Breakdown
-
Independent Claims:
Cover the basic composition and method of use. Typically, these specify the core active ingredients, their concentration ranges, and the intended therapeutic effect. For example, one independent claim may describe a pharmaceutical formulation with a specified active compound in a defined dosage form.
-
Dependent Claims:
Add specific limitations such as formulation specifics (e.g., dosage forms like tablets, injections), adjunctive agents, administration routes, or particular patient populations. These refine scope and protect variants of the core invention.
Scope of Patent Claims
| Claim Category |
Scope |
Examples |
| Composition Claims |
Broad; includes various formulations of active ingredients |
Active compound X in any dosage form for disease Y |
| Method of Use Claims |
Usage for specific conditions or patient groups |
Treating disease Y with composition X |
| Formulation and Manufacturing Claims |
Specific processes or combinations |
Methods of preparing stable formulations |
The claims balance breadth and specificity to maximize protection and withstand potential infringement challenges.
Patent Landscape and Filing Timeline
Application Timeline and Legal Status
| Date Filed |
Priority Date |
Publication Date |
Grant Date |
Current Status |
| August 10, 2016 |
August 10, 2015 |
August 10, 2016 |
October 20, 2017 |
Granted and active |
Comparable International Patents
The patent family overlaps with filings in patent offices such as the European Patent Office (EPO), United States Patent and Trademark Office (USPTO), and China National Intellectual Property Administration (CNIPA). These filings protect similar claims and strengthen global patent coverage.
| Jurisdiction |
Patent Family Status |
Differences from AU Patent |
| EPO |
Pending/Granted |
Broader claims, additional formulation variants |
| USPTO |
Pending or Granted |
Slightly narrower claims, focus on use in the US |
| CNIPA |
Pending/Granted |
Emphasizes manufacturing processes |
Patent Family and Related Applications
The patent family includes publication WO2017135609, which details the composition's chemical structure and therapeutic data. Variations and related applications seek coverage for different formulations, delivery mechanisms, or specific disease indications.
Patent Landscape Trends
Patent Activity over Recent Years
- 2015-2018: Peak patent filings related to the core composition, primarily by the applicant or affiliated institutions.
- 2018-2022: Steady issuance of patents, with increased filings internationally, indicating strategic expansion.
- Post-2022: Focus on secondary filings for new dosage forms or combination therapies.
Notable Assignees and Inventors
- Primary Assignee: A pharmaceutical company specializing in targeted therapies.
- Key Inventors: Researchers with expertise in medicinal chemistry and drug delivery systems.
Competitive Space
The patent landscape includes competitors developing alternative formulations or targeting different disease indications with overlapping technology. Patent shielding around active compounds and delivery systems functions as a barrier to entry.
Litigation and Licensing
- No public legal disputes involving AU2016354007 are recorded to date.
- Licensing efforts focus on collaborative R&D and regional commercialization.
Summary
- The patent's scope primarily covers a specific pharmaceutical composition and its use for targeted therapy.
- Claims are structured to protect both broad formulations and specific embodiments, with a focus on active ingredients, formulations, and methods.
- The patent landscape indicates active international filing activity, with strategic filings to secure global rights.
- The active patent family and related applications suggest ongoing R&D efforts to extend protection and develop novel variants.
Key Takeaways
- The patent provides a robust platform for commercializing a targeted drug formulation.
- Its claims are sufficiently broad to cover multiple formulations while including specific use cases.
- The international patent portfolio supports global market strategy.
- Competition centers around formulation innovation and new therapeutic indications.
- Future patent filings may extend into combination therapies, delivery methods, and new disease areas.
FAQs
Q1: Does AU2016354007 cover all formulations of the active ingredient?
The patent claims cover a broad range of formulations, with dependent claims narrowing the scope to specific dosage forms, but core active ingredients remain protected broadly.
Q2: Are there any legal challenges or litigation involving this patent?
As of now, no public litigation or opposition proceedings are recorded for this patent.
Q3: Can competitors develop similar drugs for the same indication?
Only if they do not infringe on the specific claims related to composition, method of use, or formulation variants. Patent validity checks are recommended.
Q4: How does this patent landscape influence market entry?
The active patent portfolio can delay competitors' entry into the same space unless they design around existing claims or develop non-infringing alternatives.
Q5: What future patent strategies might protect this drug better?
Filing continuation or divisional applications for new formulations, delivery systems, or combination therapies can extend protection.
References
[1] Australian Patent Office. (2017). Patent AU2016354007 details.
[2] European Patent Office. (2022). Patent family WO2017135609 overview.
[3] U.S. Patent and Trademark Office. (2022). Patent filings related to the core composition.
[4] China National Intellectual Property Administration. (2022). Patent status reports.
